Document:

Primus Therapeutics: Exhibit 10.9 - Filed by newsfilecorp.com

Exhibit 10.9

 

PRIMUS THERAPEUTICS, INC.

2011 EQUITY INCENTIVE PLAN 

 

TABLE OF CONTENTS 

	ARTICLE
      I GENERAL 	1
      
	   1.1
      	Purpose
      	1
      
	   1.2
      	Administration
      	1
      
	   1.3
      	Persons
      Eligible for Awards 	2
      
	   1.4
      	Types
      of Awards Under Plan 	2
      
	   1.5
      	Shares
      Available for Awards; Adjustments to Awards 	2
      
	   1.6
      	Definitions
      of Certain Terms 	6
      
	  	  	  
	
    ARTICLE
      II AWARDS UNDER THE PLAN 
	8
      
	   2.1
      	Certificates
      Evidencing Awards 	8
      
	   2.2
      	Terms
      of Stock Options and Stock Appreciation Right Awards 	8
      
	   2.3
      	Exercise
      of Options and Stock Appreciation Rights 	11
      
	   2.4
      	Compensation
      in Lieu of Exercise of an Option 	12
      
	   2.5
      	Transferability
      of Options and Stock Appreciation Rights 	13
      
	   2.6
      	Grant
      of Restricted Stock 	13
      
	   2.7
      	Right
      of Recapture 	14
      
	  	  	  
	
    ARTICLE
      III MISCELLANEOUS 
	14
      
	   3.1
      	Amendment
      of the Plan; Modification of awards 	14
      
	   3.2
      	Consent
      Requirement 	15
      
	   3.3
      	Non-assignability
      	15
      
	   3.4
      	Requirement
      of Notification of Election Under Section 83(b) of the Code 	16
      
	   3.5
      	Requirement
      of Notification Upon Disqualifying Disposition Under Section 421(b) of the
      Code 	16
      
	   3.6
      	Withholding
      Taxes 	16
      
	   3.7
      	Limitations
      Imposed by Section 162(m) 	16
      
	   3.8
      	Right
      of Discharge Reserved 	17
      
	   3.9
      	Nature
      of Payments 	17
      
	   3.10
      	 Non-Uniform
      Determinations 	18
      
	   3.11
      	 Other
      Payments or Awards 	18
      
	   3.12
      	 Headings
      	18
      
	   3.13
      	 Effective
      Date and Term of Plan 	18
      
	   3.14
      	 Restriction
      on Issuance of Stock Pursuant to Awards 	18
      
	   3.15
      	 Governing
      Law 	19
      

PRIMUS THERAPEUTICS, INC. 2011 EQUITY INCENTIVE PLAN
 

ARTICLE I 

GENERAL 

1.1 PURPOSE 

The PRIMUS THERAPEUTICS, INC. 2011 EQUITY INCENTIVE Plan (the “Plan”) is
designed to provide persons on whose initiative and efforts the successful conduct of the business of Primus Therapeutics., Inc., its subsidiaries and joint ventures (collectively the “Company”) depends, and who are responsible for
the management, growth and protection of the business of the Company, with incentives to: (a) enter into and remain in the service of the Company; (b) acquire a proprietary interest in the success of the Company; (c) maximize their individual
performance; and (d) directly or indirectly enhance the long-term performance of the Company. 

1.2 ADMINISTRATION 

(a) Administration by Committee; Constitution of Committee. The Plan shall be administered by the Compensation Committee of the Board of Directors of the Company (the “Board”) or such other
committee or subcommittee as the Board may from time to time designate or as shall be formed by the abstention or recusal of a non-Qualified Member (as defined below) of such committee (the “Committee”). The members of the Committee
shall be appointed by, and shall serve at the pleasure of, the Board. While it is intended that at all times that the Committee acts in connection with the Plan, the Committee shall consist solely of Qualified Members, the number of whom shall not
be less than two, the fact that the Committee is not so comprised will not invalidate any grant hereunder that otherwise satisfies the terms of the Plan. A “Qualified Member” is both a “non-employee director” within the meaning
of Rule 16b-3 (“Rule 16b-3”) promulgated under the Securities Exchange Act of 1934 (the “1934 Act”) and an “outside director” within the meaning of section 162(m) of the Internal Revenue Code of 1986, as
amended (the “Code”).  If the Committee does not exist, or for any other reason determined by the Board, the Board may take any action under the Plan that would otherwise be the responsibility of the Committee. 

(b) Committee’s Authority.  The Committee shall have the authority to (i) exercise all of the powers granted to it under the Plan, (ii) construe, interpret and implement the Plan and any award certificates
issued under the Plan, (iii) prescribe, amend and rescind rules and regulations relating to the Plan, including rules governing its own operations, (iv) make all determinations necessary or advisable in administering the Plan, (v) correct any
defect, supply any omission and reconcile any inconsistency in the Plan, and (vi) amend the Plan to reflect changes in applicable law. 

(c) Committee Action; Delegation.  Except as otherwise required by applicable law, actions of the Committee shall be taken by the vote of a majority of its members. Any action may be taken by a written instrument
signed by a majority of the Committee members, and action so taken shall be fully as effective as if it had been taken by a vote at a meeting. Notwithstanding the foregoing or any other provision of the Plan, the Committee (or the Board acting
instead of the Committee), may delegate to one or more officers of the Company the authority to designate the individuals (other than such officer(s)), among those eligible to receive awards pursuant to the terms of the Plan, who will receive rights
or options under the Plan and the size of each such grant, to the fullest extent permitted by Section 157 of the Delaware General Corporation Law (or any successor provision thereto), provided that the Committee shall itself grant awards to those
individuals who could reasonably be considered to be subject to the insider trading provisions of section 16 of the 1934 Act or whose awards could reasonably be expected to be subject to the deduction limitations of section 162(m) of the Code. 

(d) Determinations Final. The determination of the Committee on all matters relating to the Plan or any award under the Plan shall be final, binding and conclusive. 

(e) Limit on Committee Members’ Liability. No member of the Committee shall be liable for any action or determination made in good faith with respect to the Plan or any award thereunder. 

1.3 PERSONS ELIGIBLE FOR AWARDS 

The persons eligible to receive awards under the Plan are those officers, directors (whether or not they are employed by the Company) and executive, managerial, professional or administrative employees of, and
consultants to, the Company (collectively, “Key Persons”) as the Committee in its sole discretion shall select.

1.4 TYPES OF AWARDS UNDER PLAN 

Awards may be made under the Plan in the form of (a) incentive stock options, (b) non-qualified stock options, (c) stock appreciation rights, and (d) restricted stock, all as more fully set forth in Article II. The term
“award” means any of the foregoing. No incentive stock option may be granted to a person who is not an employee of the Company on the date of grant. Any person receiving an award under the Plan is hereinafter referred to as a
“Grantee”. 

1.5 SHARES AVAILABLE FOR AWARDS; ADJUSTMENTS TO AWARDS 

(a) Aggregate Number Available; Certificate Legends. Subject to adjustment as provided under subparagraph (d)(1) below, the total number of shares of common stock of the Company (“Common Stock”)
with respect to which awards may be granted pursuant to the Plan shall not exceed two million (2,000,000) in the aggregate. Shares issued pursuant to the Plan may be authorized but unissued Common Stock, authorized and issued Common Stock held in
the Company’s treasury or Common Stock acquired by the Company for the purposes of the Plan. The Committee may direct that any stock certificate evidencing shares issued pursuant to the Plan shall bear a legend setting forth such restrictions
on transferability as may apply to such shares. 

- 2 - 

(b) Individual Limits. Except as provided in this paragraph (b), no provision of this Plan shall be deemed to limit the number or value of shares otherwise available for awards under the Plan with respect to
which the Committee may make awards to any one eligible person.  Subject to adjustment as provided in subparagraph (d)(i) below, the total number of shares of Common Stock that may be subject to one or more awards to any one Grantee during any one
calendar year shall not exceed three hundred thousand (300,000) shares. Stock options and stock appreciation rights granted and subsequently canceled or deemed to be canceled in a calendar year shall count against this limit even after their
cancellation. 

(c) Certain Shares to Become Available Again. The following shares of Common Stock shall again become available for awards under the Plan: (i) any shares that are subject to an award under the Plan and that
remain unissued upon the cancellation or termination of such award for any reason whatsoever, and (ii) any shares of restricted stock forfeited pursuant to the terms of the Plan or the award, provided that any dividends paid on such shares are also
forfeited. 

(d) Adjustments to Available Shares and Existing Awards Upon Changes in Common Stock or Certain Other Events.  Upon certain changes in Common Stock or other corporate events, the number of shares of Common
Stock available for issuance with respect to awards that may be granted under the Plan, and that are the subject of existing awards, shall be adjusted or shall be adjustable, as follows: 

(i) Shares Available for Grants. In the event of any change in the number of shares of Common Stock outstanding by reason of any stock dividend or split, reverse stock split, recapitalization, merger,
consolidation, combination or exchange of shares or similar corporate change, the maximum number of shares of Common Stock with respect to which the Committee may grant awards under paragraph (a) above, and the individual annual limit described in
paragraph (b) above, shall be appropriately adjusted by the Committee. In the event of any change in the number of shares of Common Stock outstanding by reason of any other event or transaction, the Committee may, but need not, make such adjustments
in the number and class of shares of Common Stock with respect to which awards: (A) may be granted under Article II hereof and (B) granted to any one employee of the Company or a subsidiary during any one calendar year, in each case as the Committee
may deem appropriate. 

(ii) Outstanding Restricted Stock.  Unless the Committee in its absolute discretion otherwise determines, any securities or other property (including dividends paid in cash) received by any Grantee with respect
to a share of restricted stock which has not yet vested, as a result of any dividend, stock split, reverse stock split, recapitalization, merger, consolidation, combination, exchange of shares or otherwise, will not vest until such share of
restricted stock vests, and shall be promptly deposited with the Company or other custodian designated by the Committee. 

- 3 - 

(iii) Outstanding Options and Stock Appreciation Rights -- Increase or Decrease in Issued Shares Without Consideration. Subject to any required action by the stockholders of the Company, in the event of
any increase or decrease in the number of issued shares of Common Stock resulting from a subdivision or consolidation of shares of Common Stock or the payment of a stock dividend (but only on the shares of Common Stock), or any other increase or
decrease in the number of such shares effected without receipt of consideration by the Company, the Committee shall proportionally adjust the number of shares of Common Stock subject to each outstanding option and stock appreciation right and the
exercise price-per-share of Common Stock of each such option and stock appreciation right. 

(iv) Outstanding Options and Stock Appreciation Rights – Certain Mergers. Subject to any required action by the stockholders of the Company, in the event that the Company shall be the surviving
corporation in any merger or consolidation (except a merger or consolidation as a result of which the holders of shares of Common Stock receive securities of another corporation), each option and stock appreciation right outstanding on the date of
such merger or consolidation shall pertain to and apply to the securities which a holder of the number of shares of Common Stock subject to such option or stock appreciation right would have received in such merger or consolidation. 

(v) Outstanding Options and Stock Appreciation Rights -- Certain Other Transactions.  In the event of (1) a dissolution or liquidation of the Company, (2) a sale of all or substantially all of the
Company’s assets, (3) a merger or consolidation involving the Company in which the Company is not the surviving corporation or (4) a merger or consolidation involving the Company in which the Company is the surviving corporation but the holders
of shares of Common Stock receive securities of another corporation and/or other property, including cash, the Committee shall, in its absolute discretion, have the power to: 

(A) cancel, effective immediately prior to the occurrence of such event, each option and stock appreciation right outstanding immediately prior to such event (whether or not then exercisable), and, in full consideration
of such cancellation, pay to the Grantee to whom such option or stock appreciation right was granted an amount in cash, for each share of Common Stock subject to such option or stock appreciation right, respectively, equal to the excess of (x) the
value, as determined by the Committee in its absolute discretion, of the property (including cash) received by the holder of a share of Common Stock as a result of such event over (y) the exercise price of such option or stock appreciation right; or

- 4 - 

(B) provide for the exchange of each option and stock appreciation right outstanding immediately prior to such event (whether or not then exercisable) for an option on or stock appreciation right with respect to, as
appropriate, some or all of the property which a holder of the number of shares of Common Stock subject to such option or stock appreciation right would have received and, incident thereto, make an equitable adjustment as determined by the Committee
in its absolute discretion in the exercise price of the option or stock appreciation right, or the number of shares or amount of property subject to the option or stock appreciation right or, if appropriate, provide for a cash payment to the Grantee
to whom such option or stock appreciation right was granted in partial consideration for the exchange of the option or stock appreciation right. 

(vi) Outstanding Options and Stock Appreciation Rights -- Other Changes. In the event of any change in the capitalization of the Company or a corporate change other than those specifically referred to in
subparagraphs (iii), (iv) or (v) above, the Committee may, in its absolute discretion, make such adjustments in the number and class of shares subject to options and stock appreciation rights outstanding on the date on which such change occurs and
in the per-share exercise price of each such option and stock appreciation right as the Committee may consider appropriate to prevent dilution or enlargement of rights.  In addition, if and to the extent the Committee determines it is appropriate,
the Committee may elect to cancel each option and stock appreciation right outstanding immediately prior to such event (whether or not then exercisable), and, in full consideration of such cancellation, pay to the Grantee to whom such option or
stock appreciation right was granted an amount in cash, for each share of Common Stock subject to such option or stock appreciation right, respectively, equal to the excess of (x) the Fair Market Value of Common Stock on the date of such
cancellation over (y) the exercise price of such option or stock appreciation right. 

(vii) No Other Rights. Except as expressly provided in the Plan, no Grantee shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any
increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger or consolidation of the Company or any other corporation. Except as expressly provided in the Plan, no issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Common Stock subject to an award or the exercise price of any
option or stock appreciation right. 

- 5 - 

1.6 DEFINITIONS OF CERTAIN TERMS 

(a) The “Fair Market Value” of a share of Common Stock on any day shall be the closing price on the New York Stock Exchange, American Stock Exchange or NASDAQ (whichever is applicable) as reported for such day
in The Wall Street Journal or, if no such price is reported for such day, the average of the high bid and low asked price of Common Stock as reported for such day. If no quotation is made for the applicable day, the Fair Market Value of a share of
Common Stock on such day shall be determined in the manner set forth in the preceding sentence using quotations for the next preceding day for which there were quotations, provided that such quotations shall have been made within the ten (10)
business days preceding the applicable day.  Notwithstanding the foregoing, if deemed necessary or appropriate by the Committee, the Fair Market Value of a share of Common Stock on any day shall be determined by the Committee. In no event shall the
Fair Market Value of any share of Common Stock be less than its par value. 

(b) The term “incentive stock option” means an option that is intended to qualify for special federal income tax treatment pursuant to sections 421 and 422 of the Code as now constituted or subsequently
amended, or pursuant to a successor provision of the Code, and which is so designated in the applicable award certificate. Any option that is not specifically designated as an incentive stock option shall under no circumstances be considered an
incentive stock option. Any option that is not an incentive stock option is referred to herein as a “non-qualified stock option.” 

(c) A Grantee shall be deemed to have a “termination of employment” upon (i) the date the Grantee ceases to be employed by, or to provide consulting services for, the Company or any corporation (or any of its
subsidiaries) which assumes the Grantee’s award in a transaction to which section 424(a) of the Code applies; or (ii) the date the Grantee ceases to be a Board member, provided, however, that in the case of a Grantee (x) who is, at the time of
reference, both an employee or consultant and a Board member, or (y) who ceases to be engaged as an employee, consultant or Board member and immediately is engaged in another of such relationships with the Company, the Grantee shall be deemed to
have a “termination of employment” upon the later of the dates determined pursuant to clauses (i) and (ii) above. For purposes of clause (i) above, a Grantee who continues his or her employment or consulting relationship with: (A) a
Company subsidiary subsequent to its sale by the Company, or (B) a Company joint venture subsequent to the Company’s sale of its interests in such joint venture, shall have a termination of employment upon the date of such sale. The Committee
may in its discretion determine whether any leave of absence constitutes a termination of employment for purposes of the Plan and the impact, if any, of any such leave of absence on awards theretofore made under the Plan. 

(d) In relation to the Company, the terms “parent corporation” and “subsidiary corporation” shall be defined in accordance with sections 424(e) and (f) of the Code, respectively. 

(e) The term “employment” shall be deemed to mean an employee’s employment with, or a consultant’s provision of services to, the Company and each Board member’s service as a Board member. 

- 6 - 

(f) The term “cause” in connection with a termination of employment by reason of a dismissal for cause shall mean: 

(i) to the extent that there is an employment, severance or other agreement governing the relationship between the Grantee and the Company, which agreement contains a definition of “cause,” cause shall consist
of those acts or omissions that would constitute “cause” under such agreement; and otherwise, 

(ii) the Grantee’s termination of employment by the Company on account of any one or more of the following: 

(A) the Grantee’s willful and intentional repeated failure or refusal, continuing after notice that specifically identifies the breach(es) complained of, to perform substantially his or her material duties,
responsibilities and obligations (other than a failure resulting from Grantee’s incapacity due to physical or mental illness or other reasons beyond the control of Grantee), and which failure or refusal results in demonstrable direct and
material injury to the Company; 

(B) any willful and intentional act or failure to act by the Grantee involving fraud, misrepresentation, theft, embezzlement, dishonesty or moral turpitude (collectively, “Fraud”), that results in
demonstrable direct and material injury to the Company;

(C) the Grantee’s conviction of (or plea of nolo contendere to) an offense that is a felony in the jurisdiction involved or which is a misdemeanor in the jurisdiction involved but which involves Fraud; and

(D) a violation by the Grantee of the Company’s Code of Ethics, Insider Trading Policy and/or other code of conduct from time to time in effect.

For purposes of determining whether cause exists, no act, or failure to act, on a Grantee’s part shall be deemed “willful” or “intentional” unless done, or omitted to be done, by such Grantee in
bad faith, and without reasonable belief that his or her act or omission was in the best interests of the Company.

 Any rights the Company may have hereunder in respect of the events giving rise
 to cause shall be in addition to the rights the Company may have under any
 other agreement with a Grantee or at law or in equity. Any determination of
 whether a Grantee’s employment is (or is deemed to have been) terminated for
 cause for purposes of the Plan or any award hereunder shall be made by the
 Committee in its discretion. If, subsequent to a Grantee’s voluntary
 termination of employment or involuntary termination of employment without
 cause, it is discovered that the Grantee’s employment could have been
 terminated for cause, the Committee may deem such
Grantee’s employment to have been terminated for cause.  A Grantee’s termination of employment for cause shall be deemed for purposes of the Plan to have occurred as of the date of the occurrence of the event giving rise to cause,
regardless of when the determination of cause is made or when the termination of employment become effective. 

 - 7 - 

ARTICLE II 

AWARDS UNDER THE PLAN 

2.1 CERTIFICATES EVIDENCING AWARDS 

 Each award granted under the Plan shall be evidenced by a written certificate (an “award certificate”), which shall contain such provisions as the Committee may in its sole discretion deem necessary or desirable.  By
accepting an award pursuant to the Plan, a Grantee thereby agrees that the award shall be subject to all of the terms and provisions of the Plan and the applicable award certificate. 

2.2 TERMS OF STOCK OPTIONS AND STOCK APPRECIATION RIGHTS AWARDS 

(a) Stock Option Grants. The Committee may grant incentive stock options and non-qualified stock options (collectively, “options”) to purchase shares of Common Stock from the Company, to such Key
Persons, and in such amounts and subject to such vesting and forfeiture provisions and other terms and conditions, as the Committee shall determine in its sole discretion, subject to the provisions of the Plan. 

(b) Stock Appreciation Right Grants; Types of Stock Appreciation Rights. The Committee may grant stock appreciation rights to such Key Persons, and in such amounts and subject to such vesting and forfeiture
provisions and other terms and conditions, as the Committee shall determine in its sole discretion, subject to the provisions of the Plan. The terms of a stock appreciation right may provide that it shall be automatically exercised for a cash
payment upon the happening of a specified event that is outside the control of the Grantee and that it shall not be otherwise exercisable. Stock appreciation rights may be granted in connection with all or any part of, or independently of, any
option granted under the Plan.  A stock appreciation right granted in connection with a non-qualified stock option may be granted at or after the time of grant of such option. A stock appreciation right granted in connection with an incentive stock
option may be granted only at the time of grant of such option. 

(c) Nature of Stock Appreciation Rights. The Grantee of a stock appreciation right shall have the right, subject to the terms of the Plan and the applicable award certificate, to receive from the Company an
amount equal to (i) the excess of the Fair Market Value of a share of Common Stock on the date of exercise of the stock appreciation right over the Fair Market Value of a share of Common Stock on the date of grant (or over the option exercise price
if the stock appreciation right is granted in connection with an option), multiplied by (ii) the number of shares with respect to which the stock appreciation right is exercised. Payment upon exercise of a stock appreciation right shall be in cash
or in shares of Common Stock (valued at their Fair Market Value on the date of exercise of the stock appreciation right) or both, all as the Committee shall determine in its sole discretion. Upon the exercise of a stock appreciation right granted in
connection with an option, the number of shares subject to the option shall be reduced
by the number of shares with respect to which the stock appreciation right is exercised. Upon the exercise of an option in connection with which a stock appreciation right has been granted, the number of shares subject to the stock appreciation
right shall be reduced by the number of shares with respect to which the option is exercised. 

- 8 - 

(d) Option Exercise Price. Each award certificate with respect to an option shall set forth the amount (the “option exercise price”) payable by the Grantee to the Company upon exercise of the option
evidenced thereby.  The option exercise price per share shall be determined by the Committee in its sole discretion; provided, however, that the option exercise price shall be at least one hundred percent (100%) of the Fair Market Value of a share
of Common Stock on the date the option is granted, and provided further that in no event shall the option exercise price be less than the par value of a share of Common Stock.  Under no circumstances shall stock options be backdated. 

(e) Exercise Period. Each award certificate with respect to an option or stock appreciation right shall set forth the periods during which the award evidenced thereby shall be exercisable, whether in whole or in
part. Such periods shall be determined by the Committee in its sole discretion, subject to the following:

(i) Ten-Year Limit. No stock option (or a stock appreciation right granted in connection with an incentive stock option) shall be exercisable more than ten (10) years after the date of grant. 

(ii) Beginning of Exercise Period.  Unless the applicable award certificate otherwise provides, an option or stock appreciation right shall become exercisable with respect to a number of whole shares as close as
possible to twenty five percent (25%) of the shares subject to such option or stock appreciation right on each of the first four anniversaries of the date of grant. 

(iii) End of Exercise Period. Unless the applicable award certificate otherwise provides, once an installment becomes exercisable, it shall remain exercisable until the earlier of (A) the tenth anniversary of the
date of grant of the award or (B) the expiration, cancellation or termination of the award. 

(iv) Timing and Extent of Exercise.  Unless the applicable award certificate otherwise provides, (A) an option or stock appreciation right may be exercised from time to time as to all or part of the shares as to
which such award is then exercisable and (B) a stock appreciation right granted in connection with an option may be exercised at any time when, and to the same extent that, the related option may be exercised. 

(v) Termination of Employment -- Generally. Except as otherwise provided below, a Grantee who incurs a termination of employment may exercise any outstanding option or stock appreciation right on the following
terms and conditions: (A) exercise may be made only to the extent that the Grantee was entitled to exercise the award on the termination of employment
date; and (B) exercise must occur within three months after termination of employment but in no event after the original expiration date of the award. 

- 9 - 

(vi) Dismissal for Cause.  If a Grantee incurs a termination of employment as the result of a dismissal for cause, all options and stock appreciation rights not theretofore exercised shall terminate upon the
commencement of business on the date of the Grantee’s termination of employment. 

(vii) Disability. If a Grantee incurs a termination of employment by reason of a disability (as defined below), then any outstanding option or stock appreciation right shall be exercisable on the following terms
and conditions: (A) exercise may be made only to the extent that the Grantee was entitled to exercise the award on the termination of employment date; and (B) exercise must occur by the earlier of (I) the first anniversary of the Grantee’s
termination of employment, or (II) the original expiration date of the award. For this purpose “disability” shall mean: (x) except in connection with an incentive stock option, any physical or mental condition that would qualify a Grantee
for a disability benefit under the long-term disability plan maintained by the Company or, if there is no such plan, a physical or mental condition that prevents the Grantee from performing the essential functions of the Grantee’s position
(with or without reasonable accommodation) for a period of six consecutive months and (y) in connection with an incentive stock option, a disability described in section 422(c)(6) of the Code. The existence of a disability shall be determined by the
Committee in its absolute discretion. 

(viii) Death. 

(A) Termination of Employment as a Result of Grantee’s Death. If a termination of employment occurs as a result of a Grantee’s death, then any outstanding option or stock appreciation right shall
be exercisable on the following terms and conditions: (I) exercise may be made only to the extent that the Grantee was entitled to exercise the award on the date of death; and (II) exercise must occur by the earlier of (1) the first anniversary of
the Grantee’s termination of employment, or (2) the original expiration date of the award. 

(B) Death Subsequent to a Termination of Employment. If a Grantee dies subsequent to incurring a termination of employment but prior to the expiration of the exercise period with respect to a stock option or a
stock appreciation right, then the award shall remain exercisable until the earlier to occur of (I) the first anniversary of the Grantee’s date of death or (II) the original expiration date of the award. 

- 10 - 

(C) Restrictions on Exercise Following Death.  Any such exercise of an award following a Grantee’s death shall be made only by the Grantee’s executor or administrator or other duly appointed
representative reasonably acceptable to the Committee, unless the Grantee’s will specifically disposes of such award, in which case such exercise shall be made only by the recipient of such specific disposition. If a Grantee’s personal
representative or the recipient of a specific disposition under the Grantee’s will shall be entitled to exercise any award pursuant to the preceding sentence, such representative or recipient shall be bound by all the terms and conditions of
the Plan and the applicable award certificate which would have applied to the Grantee. 

(ix) Special Rules for Incentive Stock Options.  No option that remains exercisable for more than three months following a Grantee’s termination of employment for any reason other than death (including death
within three months after the termination of employment or within one year after a termination due to disability) or disability, or for more than one year following a Grantee’s termination of employment as the result of disability, may be
treated as an incentive stock option. 

(x) Committee Discretion.  The Committee, in the applicable award certificate, may waive or modify the application of one or more of the provisions of subparagraphs (v) through (viii) of this paragraph 2.2(e) .

(f) Incentive Stock Options: $100,000 Limitation.  To the extent that the aggregate Fair Market Value (determined as of the time the option is granted) of the stock with respect to which incentive stock
options are first exercisable by any employee during any calendar year shall exceed one hundred thousand Dollars ($100,000), or such higher amount as may be permitted from time to time under section 422 of the Code, such options shall be treated
as non-qualified stock options. 

(g) Incentive Stock Options: 10% Owners.  Notwithstanding the foregoing provisions of this Section 2.2, an incentive stock option may not be granted under the Plan to an individual who, at the time the option is
granted, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of his or her employer or of its parent or subsidiary (as such ownership may be determined for purposes of section 422(b)(6) of the
Code), unless: (i) at the time such incentive stock option is granted the option exercise price is at least one hundred ten percent (110%) of the Fair Market Value of the shares subject thereto and (ii) the incentive stock option by its terms is not
exercisable after the expiration of five (5) years from the date it is granted. 

2.3 EXERCISE OF OPTIONS AND STOCK APPRECIATION RIGHTS 

 Subject to the other provisions of this Article II, each option or stock appreciation right granted under the Plan shall be exercisable as follows: 

- 11 - 

(a) Notice of Exercise.  An option or stock appreciation right shall be exercised by the filing of a written notice with the Company or the Company’s designated transfer agent (the “Transfer
Agent”), in such form and in such manner as the Committee shall in its sole discretion prescribe. 

(b) Payment of Exercise Price. Any written notice of exercise of an option shall be accompanied by payment for the shares being purchased. Such payment shall be made: (i) by certified or official bank check (or
the equivalent thereof acceptable to the Company or its Transfer Agent) for the full option exercise price; or (ii) with the consent of the Committee, by delivery of shares of Common Stock owned by the Grantee (whether acquired by option exercise or
otherwise, provided that if such shares were acquired pursuant to the exercise of a stock option, they were acquired at least six months prior to the option exercise date or such other period as the Committee may from time to time determine) having
a Fair Market Value (determined as of the exercise date) equal to all or part of the option exercise price and a certified or official bank check (or the equivalent thereof acceptable to the Company or its Transfer Agent) for any remaining portion
of the full option exercise price; or (iii) at the discretion of the Committee and to the extent permitted by law, by such other provision, consistent with the terms of the Plan, as the Committee may from time to time prescribe. 

(c) Delivery of Certificates Upon Exercise. Promptly after receiving payment of the full option exercise price, or after receiving notice of the exercise of a stock appreciation right, the Company or its Transfer
Agent shall deliver to the Grantee or to such other person as may then have the right to exercise the award, certificate or certificates for the shares of Common Stock for which the award has been exercised. If the method of payment employed upon
option exercise so requires, and if applicable law permits, a Grantee may direct the Company, or its Transfer Agent, as the case may be, to deliver the stock certificate(s) to the Grantee’s stockbroker. 

(d) No Stockholder Rights.  No Grantee of an option or stock appreciation right (or other person having the right to exercise such award) shall have any of the rights of a stockholder of the Company with respect
to shares subject to such award until the issuance of a stock certificate to such person for such shares. Except as otherwise provided in Section 1.5(b), no adjustment shall be made for dividends, distributions or other rights (whether ordinary or
extraordinary, and whether in cash, securities or other property) for which the record date is prior to the date such stock certificate is issued. 

2.4 COMPENSATION IN LIEU OF EXERCISE OF AN OPTION 

 Upon written application of the Grantee of an option, the Committee may in its sole discretion determine to substitute, for the exercise of such option, compensation to the Grantee not in excess of the difference between the option exercise price
and the Fair Market Value of the shares covered by such written application on the date of such application.  Such compensation shall be in shares of Common Stock, and the payment thereof may be subject to conditions, all as the Committee shall
determine in its sole discretion. In the event compensation is substituted pursuant to this Section 2.4 for the exercise, in whole or in part, of an option, the number of shares subject to the option shall be reduced by the number of shares for
which such compensation is substituted. 

- 12 - 

2.5 TRANSFERABILITY OF OPTIONS AND STOCK APPRECIATION RIGHTS 

 Except as otherwise provided in an applicable award certificate evidencing an option or stock appreciation right, during the lifetime of a Grantee, each option or stock appreciation right granted to a Grantee shall be exercisable only by the
Grantee and no option or stock appreciation right shall be assignable or transferable otherwise than by will or by the laws of descent and distribution.  The Committee may, in any applicable award certificate evidencing an option (other than an
incentive stock option to the extent inconsistent with the requirements of section 422 of the Code applicable to incentive stock options), permit a Grantee to transfer all or some of the options to (A) the Grantee’s spouse, children or
grandchildren (“immediate family members”), (B) a trust or trusts for the exclusive benefit of such immediate family members, or (C) other parties approved by the Committee in its absolute discretion.  Following any such transfer, any
transferred options shall continue to be subject to the same terms and conditions as were applicable immediately prior to the transfer.  Notwithstanding the foregoing, a non-qualified stock option shall be transferable pursuant to a “domestic
relations order” as defined in the Code or Title I of the Employment Retirement Income Security Act of 19974, as amended, or related applicable regulations. 

2.6 GRANT OF RESTRICTED STOCK 

(a) Restricted Stock Grants.  The Committee may grant restricted shares of Common Stock to such Key Persons, in such amounts, and subject to such vesting and forfeiture provisions and other terms and conditions
as the Committee shall determine in its sole discretion, subject to the provisions of the Plan. Restricted stock awards may be made independently of or in connection with any other award under the Plan. A Grantee of a restricted stock award shall
have no rights with respect to such award unless such Grantee accepts the award within such period as the Committee shall specify by accepting delivery of a award certificate in such form as the Committee shall determine and, in the event the
restricted shares are newly issued by the Company, makes payment to the Company or its Transfer Agent by certified or official bank check (or the equivalent thereof acceptable to the Company) in an amount at least equal to the par value of the
shares covered by the award. 

(b) Issuance of Stock Certificate(s).  Promptly after a Grantee accepts a restricted stock award, the Company or its Transfer Agent shall issue to the Grantee a stock certificate or stock certificates for the
shares of Common Stock covered by the award or shall, at the Company’s option, establish an account evidencing ownership of the stock in uncertificated form.  Upon the issuance of such stock certificate(s), or establishment of such account, the
Grantee shall have the rights of a stockholder with respect to the restricted stock, subject to: (i) the non-transferability restrictions and forfeiture provision described in paragraphs (d) and (e) of this Section 2.6; (ii) in the Committee’s
discretion, a requirement that any dividends paid on such shares shall be held in escrow until all restrictions on such shares have lapsed; and (iii) any other restrictions and conditions contained in the applicable award certificate. 

(c) Custody of Stock Certificate(s).  Unless the Committee shall otherwise determine, any stock certificates issued evidencing shares of restricted stock shall remain in the possession of the Company until such
shares are free of any restrictions specified in the
applicable award certificate.  The Committee may direct that such stock certificate(s) bear a legend setting forth the applicable restrictions on transferability.

- 13 - 

(d) Non-transferability. Shares of restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as otherwise specifically provided in this Plan or the applicable
award certificate. The Committee at the time of grant shall specify the date or dates (which may depend upon or be related to a period of continued employment with the Company, the attainment of performance goals or other conditions or a combination
of such conditions) on which the non-transferability of the restricted stock shall lapse. 

(e) Termination of Employment. Except as may otherwise be provided by the Committee at any time prior to a Grantee’s termination of employment, all shares of restricted stock that have not then vested shall
be immediately forfeited upon (i) a Grantee’s retirement or voluntary termination of employment, or (ii) a Grantee’s dismissal for cause (as defined in Section 1.6(f)) .  Upon such forfeiture, all dividends paid on such shares, to the
extent such dividends have been set aside in an escrow account, also shall be forfeited. Except as may otherwise be provided by the Committee at any time prior to a Grantee’s termination of employment, in the event a Grantee’s employment
is terminated (i) by the Company, other than for cause, (ii) by reason of disability, or (iii) by death, all shares of restricted stock that have not vested shall immediately vest as of the termination date. 

2.7 RIGHT OF RECAPTURE 

If at any time after the date on which a Grantee has been granted or become vested in an award pursuant to the achievement of performance goals, the Committee determines that the earlier determination as to the
achievement of the performance goals was based on incorrect data and that in fact the performance goals had not been achieved or had been achieved to a lesser extent than originally determined, then (i) any award or portion of an award granted based
on such incorrect determination shall be forfeited, (ii) any award or portion of an award that became vested based on such incorrect determination shall be deemed to be not vested, and (iii) any amounts paid to the Grantee based on such incorrect
determination shall be paid by the Grantee to the Company upon notice from the Company. 

ARTICLE III 

MISCELLANEOUS 

3.1 AMENDMENT OF THE PLAN; MODIFICATION OF AWARDS 

(a) Amendment of the Plan.  The Board may from time to time suspend, discontinue, revise or amend the Plan in any respect whatsoever, except that no such amendment shall materially impair any rights or materially
increase any obligations under any award theretofore made under the Plan without the consent of the Grantee (or, upon the Grantee’s death, the person having the right to exercise the award). For purposes of this Section 3.1, any action of the
Board or the Committee that in any way alters or affects the tax treatment of any award or that in the sole discretion of the Board is necessary to prevent an award from being subject to tax under Section 409A of the Code shall not be considered to
materially impair any
rights of any Grantee. The Board shall determine, in its sole discretion, whether to submit any amendment of the Plan to shareholders for approval; in making such determination it is expected that the Board will take into account the requirements of
any exchange on which the Common Stock of the Company is listed, the prerequisites for favorable tax treatment to the Company and Grantees of awards made under the Plan, and such other considerations as the Board deems relevant. 

- 14 - 

(b) Modification of Awards. The Committee may cancel any award under the Plan.  The Committee also may amend any outstanding award certificate, including, without limitation, by amendment which would: (i)
accelerate the time or times at which the award becomes unrestricted or vested or may be exercised; (ii) waive or amend any goals, restrictions or conditions set forth in the award certificate; or (iii) waive or amend any applicable provision of the
Plan or award certificate with respect to the termination of the award upon termination of employment, provided however, that no such amendment may lower the exercise price of an outstanding option or stock appreciation right. However, any such
cancellation or amendment (other than an amendment pursuant to paragraph 1.5(d)) that materially impairs the rights or materially increases the obligations of a Grantee under an outstanding award shall be made only with the consent of the Grantee
(or, upon the Grantee’s death, the person having the right to exercise the award). Any modification of an award in a manner that would cause the award to be subject to tax under Section 409A of the Code shall be deemed null and void. 

3.2 CONSENT REQUIREMENT 

(a) No Plan Action without Required Consent. If the Committee shall at any time determine that any Consent (as hereinafter defined) is necessary or desirable as a condition of, or in connection with, the granting
of any award under the Plan, the issuance or purchase of shares or exercise of other rights thereunder, or the taking of any other action thereunder (each such action being hereinafter referred to as a “Plan Action”), then such Plan
Action shall not be taken or permitted, in whole or in part, unless and until such consent shall have been effected or obtained to the full satisfaction of the Committee. 

(b) Consent Defined. The term “consent” as used herein with respect to any Plan action means (i) any and all listings, registrations or qualifications in respect thereof upon any securities exchange or
under any federal, state or local law, rule or regulation, (ii) any and all written agreements and representations by the Grantee with respect to the disposition of shares, or with respect to any other matter, which the Committee shall deem
necessary or desirable to comply with the terms of any such listing, registration or qualification or to obtain an exemption from the requirement that any such listing, qualification or registration be made and (iii) any and all consents, clearances
and approvals in respect of a Plan Action by any governmental or other regulatory bodies. 

3.3 NON-ASSIGNABILITY 

 Except as expressly provided herein or by the terms of an award certificate: (a) no award or right granted to any person under the Plan or under any award certificate shall be assignable or transferable other than by will or by the laws of descent
and distribution; and (b) all rights
granted under the Plan or any award certificate shall be exercisable during the life of the Grantee only by the Grantee or the Grantee’s legal representative. 

- 15 - 

3.4 REQUIREMENT OF NOTIFICATION OF ELECTION UNDER SECTION 83(B) OF THE CODE 

 If any Grantee shall, in connection with the acquisition of shares of Common Stock under the Plan, make the election permitted under section 83(b) of the Code (i.e., an election to include in gross income in the year of transfer the amounts
specified in section 83(b) of the Code), such Grantee shall notify the Company of such election within 10 days of filing notice of the election with the Internal Revenue Service, in addition to any filing and notification required pursuant to
regulations issued under the authority of Code section 83(b). 

3.5 REQUIREMENT OF NOTIFICATION UPON DISQUALIFYING DISPOSITION UNDER SECTION 421(B) OF THE CODE 

 Each Grantee of an incentive stock option shall notify the Company of any disposition of shares of Common Stock issued pursuant to the exercise of such option under the circumstances described in section 421(b) of the Code (relating to certain
disqualifying dispositions), within 10 days of such disposition. 

3.6 WITHHOLDING TAXES 

(a) With Respect to Cash Payments. Whenever cash is to be paid pursuant to an award under the Plan, the Company shall be entitled to deduct therefrom an amount sufficient in its opinion to satisfy all federal,
state and other governmental tax withholding requirements related to such payment. 

(b) With Respect to Delivery of Common Stock.  Whenever shares of Common Stock are to be delivered pursuant to an award under the Plan, the Company shall be entitled to require as a condition of delivery that the
Grantee remit to the Company an amount sufficient in the opinion of the Company to satisfy all federal, state and other governmental tax withholding requirements related thereto. With the approval of the Committee, which approval shall be at the
Committee’s sole discretion, the Grantee may satisfy the foregoing condition by electing to have the Company withhold from delivery shares having a value equal to the amount of tax to be withheld. Such shares shall be valued at their Fair
Market Value as of the date on which the amount of tax to be withheld is determined. Fractional share amounts shall be settled in cash. Such a withholding election may be made with respect to all or any portion of the shares to be delivered pursuant
to an award. 

3.7 LIMITATIONS IMPOSED BY SECTION 162(M) 

Notwithstanding any other provision hereunder, if and to the extent that the Committee determines the Company’s federal tax deduction in respect of an award may be limited as a result of section 162(m) of the Code,
the Committee may take the following actions: 

(i) With respect to options or stock appreciation rights, the Committee may
delay the exercise or payment, as the case may be, in respect of such options or
stock appreciation rights until 30 days following the earlier
to occur of (A) the Grantee’s termination of employment and (B) the Company’s reasonable determination that the Company’s federal tax deduction in respect of the award will not be limited by reason of section 162(m). In the event that
a Grantee exercises an option or stock appreciation right at a time when the Grantee is a 162(m) covered employee, and the Committee determines to delay the exercise or payment, as the case may be, in respect of any such award, the Committee shall
credit cash or, in the case of an amount payable in Common Stock, the Fair Market Value of the Common Stock, payable to the Grantee to a book account. The Grantee shall have no rights in respect of such book account and the amount credited thereto
shall not be transferable by the Grantee other than by will or laws of descent and distribution.  The Committee may credit additional amounts to such book account as it may determine in its sole discretion. Any book account created hereunder shall
represent only an unfunded, unsecured promise by the Company to pay the amount credited thereto to the Grantee in the future. 

- 16 - 

(ii) With respect to restricted stock, the Committee may require the Grantee to surrender to the Committee any award certificates with respect to such awards, in order to cancel the awards of such restricted stock.  In
exchange for such cancellation, the Committee shall credit to a book account a cash amount equal to the Fair Market Value of the shares of Common Stock subject to such awards. The amount credited to the book account shall be paid to the Grantee 30
days after the earlier to occur of (A) the Grantee’s termination of employment and (B) the Company’s reasonable determination that the Company’s federal tax deduction in respect of the award will not be limited by reason of section
162(m).  The Grantee shall have no rights in respect of such book account and the amount credited thereto shall not be transferable by the Grantee other than by will or laws of descent and distribution.  The Committee may credit additional amounts
to such book account as it may determine in its sole discretion. Any book account created hereunder shall represent only an unfunded, unsecured promise by the Company to pay the amount credited thereto to the Grantee in the future. 

3.8 RIGHT OF DISCHARGE RESERVED 

 Nothing in the Plan or in any award certificate shall confer upon any Grantee the right to continue employment with the Company or affect any right that the Company may have to terminate such employment. 

3.9 NATURE OF PAYMENTS 

(a) Consideration for Services Performed. Any and all grants of awards and issuances of shares of Common Stock under the Plan shall be in consideration of services performed for the Company by the Grantee. 

(b) Not Taken into Account for Benefits. All such grants and issuances shall constitute a special incentive payment to the Grantee and shall not be taken into account in
computing the amount of salary or compensation of the Grantee for the purpose of determining any benefits under any pension, retirement, profit-sharing, bonus, life insurance or other benefit plan of the Company or under any agreement between the
Company and the Grantee, unless such plan or agreement specifically otherwise provides. 

- 17 - 

3.10 NON-UNIFORM DETERMINATIONS 

 The Committee’s determinations under the Plan need not be uniform and may be made by it selectively among persons who receive, or who are eligible to receive, awards under the Plan (whether or not such persons are similarly situated). Without
limiting the generality of the foregoing, the Committee shall be entitled, among other things, to make non-uniform and selective determinations, and to enter into non-uniform and selective award certificates, as to (a) the persons to receive awards
under the Plan, (b) the terms and provisions of awards under the Plan, and (c) the treatment of leaves of absence pursuant to Section 1.6(c) . 

3.11 OTHER PAYMENTS OR AWARDS 

 Nothing contained in the Plan shall be deemed in any way to limit or restrict the Company from making any award or payment to any person under any other plan, arrangement or understanding, whether now existing or hereafter in effect. 

3.12 HEADINGS 

 Any section, subsection, paragraph or other subdivision headings contained herein are for the purpose of convenience only and are not intended to expand, limit or otherwise define the contents of such subdivisions. 

3.13 EFFECTIVE DATE AND TERM OF PLAN 

(a) Adoption; Stockholder Approval. The Plan was adopted by the Board on November [  ], 2010, and shall become effective January 1, 2011, subject to approval by the Company’s stockholders.  All awards under
the Plan prior to such stockholder approval are subject in their entirety to such approval.  If such approval is not obtained prior to the first anniversary of the date of adoption of the Plan, the Plan and all awards thereunder shall terminate on
that date. 

(b) Termination of Plan. Unless sooner terminated by the Board or pursuant to paragraph (a) above, the provisions of the Plan respecting the grant of any award pursuant to which shares of Common Stock will be
granted shall terminate on the tenth anniversary of the adoption of the Plan by the Board, and no such awards shall thereafter be made under the Plan. All awards made under the Plan prior to the its termination of shall remain in effect until such
awards have been satisfied or terminated in accordance with the terms and provisions of the Plan and the applicable award certificates. 

3.14 RESTRICTION ON ISSUANCE OF STOCK PURSUANT TO AWARDS 

 The Company shall not permit any shares of Common Stock to be issued pursuant to awards granted under the Plan unless such shares of Common Stock are fully paid and non-assessable, within the meaning of Section 152 of the Delaware General Corporation Law, except as otherwise permitted by Section 153(c) of the Delaware General Corporation Law. 

- 18 - 

3.15 GOVERNING LAW 

 Except to the extent preempted by any applicable federal law, the Plan will be construed and administered in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of laws. 

- 19 -Primus Therapeutics, Inc.: Exhibit 10.12 - Filed by newsfilecorp.com

Exhibit 10.12

DANA HOLDINGS, LLC

4390 U.S. Route 1 

Suite 200 

Princeton, NJ 08540 

November 10, 2010

Primus Therapeutics, Inc.

23 Orchard Road, Suite 105

Skillman, NJ 08558

Attention: Dennis M. O’Donnell, President & Chief Executive Officer

 Re: Consulting Agreement 

Dear Mr. O’Donnell;

This letter agreement (the “Agreement”), which amends and restates our agreement dated as of July 1, 2010 (the “Original Agreement”), sets forth the terms and conditions upon which Dana Holdings, LLC
(“Dana”) will provide management, business and strategic consulting services to Primus Therapeutics, Inc. (the “Company”). 

1. Engagement. The Company hereby engages Dana for the term of this Agreement, and Dana hereby agrees to act, as the Company’s exclusive external management and strategic business consultant, to provide the Services
specified in Section 2 hereof. 

2. Services. Dana shall, as and to the extent requested by the Company, perform the following services (the “Services”): 

	
 	
 	
a. 		
Assistance in developing a strategic business plan for the launch of the Company’s proprietary over-the-counter brands and brand products;

	
	 	 	 	 
	
 	
 	
b. 		
Assistance in identifying third party licensors and manufacturers to collaborate with the Company in the development and manufacture of the Company’s product line, including advice regarding the commercial terms and
conditions of any contractual arrangements entered into with any such third parties;

	
	 	 	 	 
	
 	
 	
c. 		
Advice concerning the marketing, distribution and sale of the Company’s product line, including assisting the Company in development of product labeling and packaging, presentations to retailers, etc.;

	

Primus Therapeutics, Inc.

November 10, 2010 

Page 2 

	
 	
 	
d. 		
Assistance with the preparations for an initial public offering (the “IPO”), including liaison with underwriters and company counsel and assistance in drafting the applicable Prospectus;

	
	 	 	 	 
	
 	
 	
e. 		
Strategic planning and business development; and

	
	 	 	 	 
	
 	
 	
f. 		
Such other financial and strategic advisory services as the management of Primus may from time to time request.

	

Dana shall report to the President and Chief Executive Officer of the Company, or such other person(s) as the Company, through its Chief Executive Officer and/or Board of Directors may from time to time designate. 

3. Compensation. In consideration of the performance of the Services by Dana, the Company shall pay Dana the following amounts: 

	
 	
 	
a. 		
As and from July 1, 2010 through the closing of the IPO (the “IPO Closing”) or the termination of this Agreement, whichever shall first occur, and in lieu of any other compensation for any Services performed by
Dana prior to the IPO Closing, the Company shall pay Dana a non-accountable expense allowance of $15,000 per calendar month, which amount shall become due and payable on the first day of such calendar month. In the case of the payment for the
month in which the IPO Closing occurs, the pro-rated portion of such the payment that is attributable to the period commencing on the date of the IPO Closing and ending on the final day of such calendar month shall be credited against the first
payment due pursuant to clause b., below;

	
	 	 	 	 
	
 	
 	
b. 		
As and from the IPO Closing, the Company shall pay Dana a consulting fee of Eighty Thousand Dollars ($80,000) per calendar month. The first such payment shall be due upon the date of the IPO Closing, shall be pro-rated for the
period commencing on the date of the IPO Closing and ending on the final day of the calendar month in which the IPO Closing occurs, and shall be reduced by the amount of any credit arising pursuant to the final sentence of clause a., above. Payments
for subsequent calendar months shall become due and payable on the first day of such calendar month;

	
	 	 	 	 
	
 	
 	
c. 		
As and from the IPO Closing, the Company shall promptly reimburse Dana for any actual and documented expenses reasonably incurred by Dana in performing Services pursuant to clause b., above, provided, however, that any
expenditure for air travel or hotel accommodation shall require the Company’s advance approval.

	

Primus Therapeutics, Inc.

November 10, 2010 

Page 3 

4. Proprietary Work Product. The Company acknowledges and agrees that any work product produced by Dana pursuant to this Agreement is intended for the sole use of the Company and may not be distributed or disclosed to any
third party without Dana’s prior written consent.

5. Confidential Information. Dana acknowledges and agrees that, in performing Services hereunder, it has acquired, or may in the future acquire, confidential information of the Company, including but not limited to
business and marketing plans, market surveys, contractual arrangements, financial statements and projections, cost, sales and profitability data, technical records, patent applications, production schedules, customer lists, names and addresses of
suppliers and vendors, tax information, mailing lists and personnel and salary information, in whatsoever form transmitted (“Confidential Information”), provided, however that the term “Confidential Information”
shall not include any information (i) that Dana can document was lawfully in its possession prior to any disclosure thereof by the Company; (ii) is obtained on a non-confidential basis from a source other than the Company, provided such source has a
lawful right to disclose such Confidential Material; or (iii) is or becomes in the public domain. Dana shall use the Confidential Material solely for purposes of performing the Services and, following the termination of this Agreement, and within
five (5) Business Days after being requested in writing by Primus, shall promptly either return all Confidential Information or provide a written certification, signed by a Managing Director of Dana, that all such Confidential Information has been
destroyed. The foregoing notwithstanding, Dana may disclose Confidential Information if and to the extent (but only to the extent) required by applicable law, court order or other legal process, provided, however, that in the event of a
demand for disclosure pursuant to this paragraph, Dana shall, as soon as is reasonably practical and unless prohibited by law, notify the Company of such demand, in order that the Company may seek a protective order or other remedy. In the event
that such protective order or other remedy is not obtained, Dana may furnish only that portion of the Confidential Information that it is advised by counsel is legally required. 

 Dana acknowledges that the Confidential Information has competitive value and that, in the event of any breach of this Section, the Company may be irreparably harmed and may not be made whole by monetary damages, and that the Company, in addition
to any other remedy to which it may be entitled in law or in equity, will therefore be entitled to seek an injunction to prevent a breach of this Section and/or to compel specific performance thereof. Dana agrees not to oppose the granting of
equitable relief on the grounds that money damages are adequate, and agrees to waive any requirements for the securing or posting of any bond in connection with such remedy. 

Dana further acknowledges that the Confidential Information may contain information that constitutes, or may in the future constitute, material non-public information for purposes of United States securities laws. Dana is aware (and shall ensure
that any of its officers, directors, employees, agents or representatives who receive the Confidential Information) are aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities by any person who
has received material, non-public information from the issuer of such securities,
and on the communication of such information to any person in circumstances such that it is reasonably foreseeable that such other person is likely to purchase or sell securities in reliance upon such information. 

Primus Therapeutics, Inc.

November 10, 2010 

Page 4 

6. Company Cooperation; Reliance on Company’s Information. The Company acknowledges that the ability of Dana to perform its Services under this Agreement requires the reasonable cooperation and assistance of the
Company and its personnel. Accordingly, the Company shall furnish to Dana (subject to Section 5 hereof) all such information, documents and other materials as Dana may reasonably request, to the extent in the Company’s possession. The Company
further acknowledges that Dana, in performing Services under this Agreement, will be relying on the truth, completeness and accuracy of the written documentation delivered and the verbal communications made by the Company and its representatives to
Dana and its representatives in connection with all matters relating to the performance of Services by Dana hereunder.

7. Expiration; Termination. This Agreement shall be deemed effective as of July 1, 2010 and shall continue in effect until the anniversary date of the IPO Closing. The Agreement shall thereafter renew automatically for
additional one-year periods unless cancelled by either party by written notice given not more than three (3) and not less than two (2) months prior to expiration of the then-current term, provided that in the event the Company cancels the Agreement
(other than pursuant to the following sentence) the Company shall on the date such cancellation becomes effective pay Dana a termination fee of Six Hundred Thousand Dollars ($600,000). The foregoing withstanding, either party may terminate this
Agreement upon thirty (30) days written notice to the other (a) in the event of any material breach of this Agreement by such other party, if such breach has not been remedied within such thirty (30) day notice period, or (b) if the IPO Closing has
not occurred by July 30, 2011.

8. Indemnification. Notwithstanding any provision in this Agreement to the contrary, the Company agrees that neither Dana nor its affiliates, nor their respective officers, directors, employees, agents or representatives,
shall have any liability (whether direct or indirect, in contract, tort or otherwise) to the Company for or in connection with this Agreement and the Services performed by Dana hereunder, except as to losses, claims, damages or liabilities
“Liabilities”) incurred by the Company that are finally judicially determined to have resulted from the bad faith or gross negligence of such individuals or entities. The Company shall indemnify and hold harmless Dana from and
against any Liabilities incurred by Dana in accordance with the indemnification provisions set forth on Exhibit A hereto. 

9. Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, and any dispute arising under or out of this Agreement shall be subject to the
exclusive jurisdiction of the state or Federal courts sitting in New York County. Each party hereby expressly and irrevocably (i) consents to the jurisdiction of the state and Federal courts sitting in New York County and (ii) waives any objection
that it may now or hereafter have to venue in New York County, whether based on forum non conveniens or otherwise, and (iii) agrees that service of process in any such suit,
action or proceeding arising hereunder shall be deemed valid and effective if made by certified mail to the address specified in Section 12 hereof. 

Primus Therapeutics, Inc.

November 10, 2010 

Page 5 

10. Waiver of Jury Trial. Each of the parties to this Agreement hereby waives its right to a jury trial with respect to any claim, action, suit or proceeding made or brought by one of the parties against the others in
connection with or arising under this Agreement. 

11. Notice. All notice given hereunder shall be in writing, shall be delivered by overnight courier, certified mail or by e-mail in .pdf format and shall be addressed as follows: 

	
If to The Company:
	
	
Primus Therapeutics, Inc.
	
	
 
	
	
23 Orchard Road, Suite 105
	
	
 
	
	
Skillman, NJ 08558
	
	
 
	
	
Attention: Dennis M. O’Donnell, President &
	
	
 
	
	
Chief Executive Officer
	
	
 
	
	
Telephone: 908-601-1338
	
	
 
	
	
E-mail: dodonnell@primus.us.co
	
	
 
	
 
	
If to Dana:
	
	
Dana Holdings, LLC
	
	
 
	
	
4390 U.S. Route 1, Suite 200
	
	
 
		
Princeton, NJ 08543
	
	
 
		
Attention: Joseph A. Falsetti, Managing Director
	
	
 
		
Telephone: 215-262-4037
	
	
 
		
E-mail: jfalsetti@danaholdings.com
	

12. Successors and Assigns. This Agreement shall inure to the benefit of, and be binding upon, each of Dana and The Company and their respective successors-in-interest and permitted and assigns. Neither party may assign
its rights or delegate its obligations under this Agreement without the written consent of the other party, which consent shall not be unreasonably withheld or delayed. 

13. Amendments. This Agreement may be amended or terminated, or any provision hereof waived, only be an agreement in writing signed by both parties or, in the case of waiver, by the party charged. Any waiver shall be
construed strictly in accordance with its terms and shall not be construed as a continuing waiver or a waiver or any provision other than that expressly specified. 

14. No Waiver; Cumulative Remedies. No failure or delay on the part of either party in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any
such right, power or remedy preclude the exercise of any other right, power or remedy. The remedies herein provided are cumulative and not exclusive of any remedies provided by law. 

15. Headings. Headings in this Agreement are for convenience only and shall not be used to interpret or construe its provisions. 

Primus Therapeutics, Inc.

November 10, 2010 

Page 6 

16. Independent Contractor Relationship. Nothing in this Agreement shall be deemed to constitute either party as the partner or agent of the other, or otherwise confer upon either party the right to bind the other party
contractually. 

17. Survival. The provisions of Sections 4, 5, 8, 9, 10, 11, 16 and 17 shall survive the termination or expiration of this Agreement. 

18. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

19. Original Agreement. This Agreement amends and re-states the Original Agreement and any Services performed, or amounts paid, pursuant to the Original Agreement shall be treated as having being performed and paid, as
the case may be, pursuant to this Agreement. 

[Remainder of Page Intentionally Blank]

 

 

Primus Therapeutics, Inc.

November 10, 2010 

Page 7 

 Kindly confirm your agreement to the foregoing by signing a copy of this letter and return the same to us at your earliest convenience. We look forward to a long and mutually productive relationship. 

Sincerely, 

DANA HOLDINGS, LLC

	
 	
By:
/s/ Joseph A. Falsetti
	
	
 
		
      
Joseph A. Falsetti, Managing Director
	

Agreed to and accepted this 10th day of November, 2010

PRIMUS THERAPEUTICS, INC. 

	
By:
		
/s/ Dennis M. O’Donnell
	
	
 
		
Dennis M. O’Donnell
	
	
 
		
President & Chief Executive Officer
	

Exhibit A

Indemnification Provisions

 In consideration of the agreement of Dana Holdings, LLC (“Dana”) to perform Services under the attached Agreement, Primus Therapeutics, Inc. (the “Company”) shall indemnify and hold harmless Dana, its affiliates,
and their respective officers, directors, employees, agents and representatives (each such other, an “Indemnified Person”) from and against any losses, claim, damages or liability (a “Liability”) related to, arising
out of or in connection with the performance of Services by Dana pursuant to this Agreement, and shall reimburse each Indemnified Person for all expenses (including reasonable fees and expenses of counsel) incurred in connection with investigating,
preparing, pursuing or defending any such Liability, whether or not pending or threatened and whether or not any Indemnified Person is a party. The Company will not however, be responsible for any Liability (or expenses relating thereto) that is
finally judicially determined to have resulted from the willful misconduct, acts of bad faith or gross negligence of any Indemnified Person or that result from a material breach of contract of any Indemnified Person.

The Company will not, without Dana’s prior written consent, settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any action, claim, suit or proceeding to which any Indemnified Person is a party and in
respect of which indemnification may be sought hereunder, unless such settlement, compromise, consent or termination includes a release of each Indemnified Person party thereto from any Liability arising out of such action, claim, suit or
proceeding. No Indemnified Person seeking indemnification, reimbursement or contribution under this agreement will, without the Company’s prior written consent, settle, compromise, consent to the entry of any judgment in or otherwise seek to
terminate any action, claim, suit, investigation or proceeding referred to in the preceding paragraph. 

If the indemnification provided for in the first paragraph of this agreement is judicially determined to be unavailable (other than in accordance with the second sentence of the first paragraph hereof) to an Indemnified Person in respect of any
Liability referred to herein, then, in lieu of indemnifying such Indemnified Person hereunder, the Company shall contribute to the amount paid or payable by such Indemnified Person as a result of such Liability (and reasonable expense relating
thereto) (i) in such proportion as is appropriate to reflect the relative benefits to the applicable Indemnified Person, on the one hand, and the Company, on the other hand, of the Agreement, or (ii) if the allocation provided by clause (i) above is
not available, in such proportion as is appropriate to reflect not only the relative benefits referred to in such clause (i) but also the relative fault of each of the applicable Indemnified Person and the Company, as well as any other relevant
equitable considerations; provided, however, that in no event shall any Indemnified Person’s aggregate contribution to the amount paid or payable exceed the aggregate amount of fees actually received by Dana in connection with the
provision of Services under the Agreement. For the purposes of the foregoing, the relative benefits to the Company and the applicable Indemnified Person of the Engagement shall be deemed to be in the same proportion as (a) the total value paid or
contemplated to be paid or received or contemplated to be received by the Company or its shareholders, as the case may be, in the Transaction or Transactions
contemplated by the Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to Dana in connection with the transactions contemplated by the Agreement. 

A-1

Upon becoming aware of any claim that may give rise to indemnification not involving a Third Party Claim (as defined below), the Indemnified Person shall, as promptly as practicable following the date the Indemnified Person has obtained such
knowledge, give written notice of such claim for which indemnification is sought (each, a “Claim”) to the Company, but no failure to give such notice shall relieve the Company of any liability hereunder (except to the extent the
Company has suffered actual, irreversible and material economic prejudice thereby). The Indemnified Person, at its cost, shall furnish to the Company in good faith and in reasonable detail such information as the Indemnified Person may have with
respect to such Claim. 

Promptly after receipt by an Indemnified Person of notice of the commencement of any action, suit or proceeding involving a Claim by a third party (each, a “Third Party Claim”) against it, such Indemnified Person shall give written
notice to the Company of the commencement of such Third Party Claim, and shall give the Company such information with respect thereto as the Company may reasonably request, but no failure to give such notice shall relieve the Company of any
liability hereunder (except to the extent the Company has suffered actual, irreversible and material economic prejudice thereby). The Company shall have the right, but not the obligation, to assume the defense and control the settlement of such
Third Party Claim, at the Company’s cost and expense (and not as a reduction in the amount of indemnification available hereunder), using counsel selected by the Company and reasonably acceptable to the Indemnified Person. If the Company
satisfies the requirements of this agreement and desires to exercise its right to assume the defense and control the settlement of such Third Party Claim, the Company shall give written notice (the “Notice”) to the Indemnified
Person within fourteen (14) calendar days of receipt of notice from the Indemnified Person of the commencement or assertion of such Third Party Claim, stating that the Company shall be responsible therefor. Notwithstanding the foregoing, the
Indemnified Person shall have the right: (i) to assume the defense and control the settlement of a Third Party Claim and (ii) to employ separate counsel at the Company‘s reasonable expense (provided that the Company shall not be required to
reimburse the expenses and costs of more than one law firm) and control its own defense of a Third Party Claim if (x) the named parties to any such action (including any impleaded parties) include both the Indemnified Person and the Company , and
the Indemnified Person shall have been advised by counsel that there are one or more legal or equitable defenses available to the Indemnified Person that are different from those available to the Company, (y) such Third Party Claim involves
equitable or other non-monetary damages or in the reasonable judgment of the Indemnified Person, such settlement would have a continuing material adverse effect on the Indemnified Person’s business (including any material impairment of its
relationships with customers and suppliers) or (z) in the reasonable judgment of the Indemnified Person, the Company may not be able to satisfy fully such Third Party Claim. In addition, if the Company fails to give the Indemnified Person the Notice
in accordance with the terms hereof, the Indemnified Person shall have the right to assume control of the defense of and settle the Third Party Claim and all costs incurred in connection therewith shall constitute damages of the Indemnified Person.
For the avoidance of doubt, the Company acknowledges that the Company will advance any retainer fees required by legal counsel to an Indemnified Person simultaneously
with the engagement by such Indemnified Person of such counsel, it being understood and agreed that the amount of such retainer shall not exceed $20,000 and that such retainer shall be credited to fees incurred with the balance (if any)
refundable to the Company. 

A-2

If at any time after the Company assumes the defense of a Third Party Claim, any of the conditions set forth in the paragraph above are no longer satisfied, the Indemnified Person shall have the same rights as set forth above as if the Company never
assumed the defense of such claim. 

Notwithstanding the foregoing, the Company or the Indemnified Person, as the case may be, shall have the right to participate, at its own expense, in the defense of any Third Party Claim that the other party is defending. 

If the Company assumes the defense of any Third Party Claim in accordance with the terms hereof, the Company shall have the right, upon 30 calendar days’ prior written notice to the Indemnified Person, to consent to the entry of judgment with
respect to, or otherwise settle such Third Party Claim; provided, however, that with respect to such consent to the entry of judgment or settlement, the Indemnified Person will not have any liability and will be fully indemnified with respect to all
Third Party Claims. Notwithstanding the foregoing, the Company shall not have the right to consent to the entry of judgment with respect to, or otherwise settle a Third Party Claim if: (i) the consent to judgment or settlement of such Third Party
Claim involves equitable or other non-monetary damages against the Indemnified Person, or (ii) in the reasonable judgment of the Indemnified Person, such settlement would have a continuing effect on the Indemnified Person’s business (including
any material impairment of its relationships with customers and suppliers), without the prior written consent of the Indemnified Person. In addition, the Indemnified Person shall have the sole and exclusive right to settle any Third Party Claim on
such terms and conditions as it deems reasonably appropriate, (x) if the Company fails to assume the defense in accordance with the terms hereof, or (y) to the extent such Third Party Claim involves only equitable or other non-monetary relief, and
shall have the right to settle any Third Party Claim involving monetary damages with the Company’s consent, which consent shall not be unreasonably withheld. 

The provisions of this Exhibit A shall apply to Agreement and any modification thereof and shall remain in full force and effect regardless of any termination or the completion of Dana’s Services under the Agreement. 

 

 

A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]